Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 11, 2016, Pages 2862-2871

  Willame, Corinne ^a   Rosillon, Dominique ^a   Zima, Julia ^a   Angelo, Maria Genalin ^a   Stuurman, Anke L ^b   Vroling, Hilde ^b   Boggon, Rachael ^c   Bunge, Eveline M ^b   Pladevall Vila, Manel ^d,e   Baril, Laurence ^a  

^a GSK   (Belgium)

^b Pallas Health Research and Consultancy   (Netherlands)

^c CPRD Research Group   (United Kingdom)

^d RTI HEALTH SOLUTIONS   (United States)

^e HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

autoimmune conditions; human papilloma virus; human papillomavirus vaccine; post licensure safety study; vaccination; vaccine safety

Indexed keywords

WART VIRUS VACCINE; ALUMINUM HYDROXIDE; ASO4 MIXTURE; LIPID A;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; CHILD; CONTROLLED STUDY; CROHN DISEASE; FEMALE; FOLLOW UP; GENDER; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SCHOOL CHILD; SENSITIVITY ANALYSIS; UNITED KINGDOM; VACCINATION; YOUNG ADULT; ANALOGS AND DERIVATIVES; AUTOIMMUNE DISEASES; CHEMICALLY INDUCED; RISK ASSESSMENT;

ADOLESCENT; ADULT; ALUMINUM HYDROXIDE; AUTOIMMUNE DISEASES; CHILD; FEMALE; HUMANS; LIPID A; PAPILLOMAVIRUS VACCINES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; UNITED KINGDOM; YOUNG ADULT;

EID: 84983503748     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1199308     Document Type: Article

References (26)

1. Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol 2010; 117:S5-10; PMID:20304221; http://dx.doi.org/10.1016/j.ygyno.2010.01.024
2. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al. Human papillomavirus genotype attribution in invasive cervical cancer:a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11:1048-56; PMID:20952254; http://dx.doi.org/10.1016/S1470-2045(10)70230-8
3. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, Skinner SR, Apter D, Naud P, Salmeron J, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia:4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:89-99; PMID:22075171; http://dx.doi.org/10.1016/S1470-2045(11)70286-8
4. Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmeron J, Del Rosario-Raymundo MR, Verheijen RH, Quek SC, da Silva DP, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years:4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet 2014; 384:2213-27; PMID:25189358; http://dx.doi.org/10.1016/S0140-6736(14)60920-X
5. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types:4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:100-10; PMID:22075170; http://dx.doi.org/10.1016/S1470-2045(11)70287-X
6. Klein NP, Ray P, Carpenter D, Hansen J, Lewis E, Fireman B, Black S, Galindo C, Schmidt J, Baxter R. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine 2010; 28:1062-8; PMID:19896453; http://dx.doi.org/10.1016/j.vaccine.2009.10.115
7. Guimaraes LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. Pharmacol Res 2015; 100:190-209; PMID:26275795; http://dx.doi.org/10.1016/j.phrs.2015.08.003
8. Angelo MG, David MP, Zima J, Baril L, Dubin G, Arellano F, Struyf F. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf 2014; 23:466-79; PMID:24644063; http://dx.doi.org/10.1002/pds.3554
9. MHRA Public Assessment Report - Cervarix HPV vaccine:safety update at end of 4 years routine use in HPV immunisation programme. London:MHRA, 2012
10. Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention:a pooled analysis of 11 clinical trials. Hum Vaccin 2009; 5:332-40; PMID:19221517; http://dx.doi.org/10.4161/hv.5.5.7211
11. Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, Zahaf T, Catteau G, Geeraerts B, Descamps D. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine:final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother 2014; 10:2147-62; PMID:25424918; http://dx.doi.org/10.4161/hv.29532
12. Angelo MG, Zima J, Tavares Da Silva F, Baril L, Arellano F. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine:more than 4 years of experience. Pharmacoepidemiol Drug Saf 2014; 23:456-65; PMID:24644078; http://dx.doi.org/10.1002/pds.3593
13. Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H, Ackerson B, Cheetham TC, Hansen J, Deosaransingh K, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2012; 271:193-203; PMID:21973261; http://dx.doi.org/10.1111/j.1365-2796.2011.02467.x
14. Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, Sparen P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden:cohort study. BMJ 2013; 347:f5906; PMID:24108159; http://dx.doi.org/10.1136/bmj.f5906
15. Jacobsen SJ, Sy LS, Ackerson BK, Chao CR, Slezak JM, Cheetham TC, Takhar HS, Velicer CM, Hansen J, Klein NP. An unmasking phenomenon in an observational post-licensure safety study of adolescent girls and young women. Vaccine 2012; 30:4585-7; PMID:22580356; http://dx.doi.org/10.1016/j.vaccine.2012.04.103
16. Scheller NM, Svanstrom H, Pasternak B, Arnheim-Dahlstrom L, Sundstrom K, Fink K, Hviid A. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA 2015; 313:54-61; PMID:25562266; http://dx.doi.org/10.1001/jama.2014.16946
17. Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, Kulldorff M, Lewis E, Fireman B, Daley MF, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine:findings from the vaccine safety datalink. Vaccine 2011; 29:8279-84; PMID:21907257; http://dx.doi.org/10.1016/j.vaccine.2011.08.106
18. Grimaldi-Bensouda L, Guillemot D, Godeau B, Benichou J, Lebrun-Frenay C, Papeix C, Labauge P, Berquin P, Penfornis A, Benhamou PY, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med 2014; 275:398-408; PMID:24206418; http://dx.doi.org/10.1111/joim.12155
19. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302:750-7; PMID:19690307; http://dx.doi.org/10.1001/jama.2009.1201
20. Williams T, van Staa T, Puri S, Eaton S. Recent advances in the utility and use of the general practice research database as an example of a UK primary care data resource. Ther Adv Drug Saf 2012; 3:89-99; PMID:25083228; http://dx.doi.org/10.1177/2042098611435911
21. Thomas KH, Davies N, Metcalfe C, Windmeijer F, Martin RM, Gunnell D. Validation of suicide and self-harm records in the clinical practice research datalink. Br J Clin Pharmacol 2013; 76:145-57; PMID:23216533; http://dx.doi.org/10.1111/bcp.12059
22. Crawford CaW J. Health Protection Agency survey of Primary Care Trust teenage vaccination programmes. Health Protection Agency 2009
23. Sheridan AaW J. Annual HPV vaccine uptake in England:2008/09:Routine programme for year 8 girls (12–13 years old) and catch-up campaign for year 13 girls (17–18 years old). Health Protection Agency Department of Health, 2009
24. Sheridan AaW J. Annual HPV vaccine coverage in England in 2009/2010. Health Protection Agency Department of Health, 2010
25. Annual HPV vaccine coverage in England in 2010/11. Health Protection Agency, 2012
26. Tavares Da Silva F, De Keyser F, Lambert PH, Robinson WH, Westhovens R, Sindic C. Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. Vaccine 2013; 31:1870-6; PMID:23391600; http://dx.doi.org/10.1016/j.vaccine.2013.01.042